Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.

Agnieszka Dabrowska; Artur Szczepanski; Pawel Botwina; Natalia Mazur-Panasiuk; Helena Jirincova; Lukasz Rabalski; Tomas Zajic; Grzegorz Popowicz; Krzysztof Pyrc

Este artigo é um Preprint

Preprints são relatos preliminares de pesquisa que não foram certificados pela revisão por pares. Eles não devem ser considerados para orientar a prática clínica ou comportamentos relacionados à saúde e não devem ser publicados na mídia como informação estabelecida.

Preprints publicados online permitem que os autores recebam feedback rápido, e toda a comunidade científica pode avaliar o trabalho independentemente e responder adequadamente. Estes comentários são publicados juntamente com os preprints para qualquer pessoa ler e servir como uma avaliação pós-publicação.

Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.

Agnieszka Dabrowska; Artur Szczepanski; Pawel Botwina; Natalia Mazur-Panasiuk; Helena Jirincova; Lukasz Rabalski; Tomas Zajic; Grzegorz Popowicz; Krzysztof Pyrc.

Afiliação

Agnieszka Dabrowska; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387, Krakow, Poland
Artur Szczepanski; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387, Krakow, Poland
Pawel Botwina; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387, Krakow, Poland
Natalia Mazur-Panasiuk; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387, Krakow, Poland
Helena Jirincova; National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Public Health, Srobarova 49/48, 100-00, Prague, Czech Republic.
Lukasz Rabalski; Laboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology of University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307, Gdan
Tomas Zajic; Liberec Regional Hospital, Husova 357/10, 460 01 Liberec, Czech Republic.
Grzegorz Popowicz; Institute of Structural Biology, Helmholtz Zentrum Munchen, Ingolstadter Landstrasse 1, 85764 Neuherberg, Germany.
Krzysztof Pyrc; Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, 30-387, Krakow, Poland

Preprint em Inglês | bioRxiv | ID: ppbiorxiv-473268

ABSTRACT

ABSTRACT

The Omicron variant of the SARS-CoV-2 virus was first detected in South Africa in November 2021. The analysis of the sequence data in the context of earlier variants suggested that it may show very different characteristics, including immune evasion and increased transmission. These assumptions were partially confirmed, and the reduction in protection in convalescent patients and vaccinated individuals have been confirmed. Here, we have evaluated the efficacy of antivirals against SARS-CoV-2 variants, Omicron, Delta, and the early 2020 isolate.

Licença

cc_no

Texto completo

Adicionar na Minha BVS

Imprimir

XML

Buscar no Google

Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Experimental_studies Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint

Texto completo

Adicionar na Minha BVS

Imprimir

XML

Buscar no Google